Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.

Xia Y, Chang T, Wang Y, Liu Y, Li W, Li M, Fan HY.

PLoS One. 2014 Mar 12;9(3):e91770. doi: 10.1371/journal.pone.0091770. Erratum in: PLoS One. 2016;11(3):e0152712.

2.

Hippo pathway effector Yap is an ovarian cancer oncogene.

Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S.

Cancer Res. 2010 Nov 1;70(21):8517-25. doi: 10.1158/0008-5472.CAN-10-1242.

3.

YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.

Xia Y, Zhang YL, Yu C, Chang T, Fan HY.

PLoS One. 2014 Nov 4;9(11):e109575. doi: 10.1371/journal.pone.0109575.

4.

The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.

Shimomura T, Miyamura N, Hata S, Miura R, Hirayama J, Nishina H.

Biochem Biophys Res Commun. 2014 Jan 17;443(3):917-23. doi: 10.1016/j.bbrc.2013.12.100.

PMID:
24380865
5.

The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.

Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T, Kishimoto H.

Int J Oncol. 2015;46(6):2364-70. doi: 10.3892/ijo.2015.2948.

PMID:
25846049
6.

Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.

Yan L, Cai Q, Xu Y.

Arch Biochem Biophys. 2014 Nov 15;562:31-6. doi: 10.1016/j.abb.2014.07.024.

7.

FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.

Fan Q, Cai Q, Xu Y.

Oncotarget. 2015 Sep 29;6(29):27688-99. doi: 10.18632/oncotarget.4280.

8.

A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.

Tan G, Cao X, Dai Q, Zhang B, Huang J, Xiong S, Zhang Yy, Chen W, Yang J, Li H.

Oncotarget. 2015 Apr 20;6(11):8676-86.

9.

Tumor suppressor LATS1 is a negative regulator of oncogene YAP.

Hao Y, Chun A, Cheung K, Rashidi B, Yang X.

J Biol Chem. 2008 Feb 29;283(9):5496-509.

10.

Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.

Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y, Jiang Y, Sun S, Zheng Y, Li N, Huang L.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E89-98. doi: 10.1073/pnas.1319190110. Erratum in: Proc Natl Acad Sci U S A. 2016 Nov 14;:.

11.

Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.

Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K.

Gastroenterology. 2013 Jun;144(7):1530-1542.e12. doi: 10.1053/j.gastro.2013.02.009.

12.

Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer.

Lim B, Park JL, Kim HJ, Park YK, Kim JH, Sohn HA, Noh SM, Song KS, Kim WH, Kim YS, Kim SY.

Carcinogenesis. 2014 May;35(5):1020-7. doi: 10.1093/carcin/bgt409.

PMID:
24325916
13.

The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass.

Nishioka N, Inoue K, Adachi K, Kiyonari H, Ota M, Ralston A, Yabuta N, Hirahara S, Stephenson RO, Ogonuki N, Makita R, Kurihara H, Morin-Kensicki EM, Nojima H, Rossant J, Nakao K, Niwa H, Sasaki H.

Dev Cell. 2009 Mar;16(3):398-410. doi: 10.1016/j.devcel.2009.02.003.

14.

Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells.

Ma L, Cui J, Xi H, Bian S, Wei B, Chen L.

Cancer Biol Ther. 2016;17(1):36-47. doi: 10.1080/15384047.2015.1108488.

15.

YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression.

He C, Lv X, Hua G, Lele SM, Remmenga S, Dong J, Davis JS, Wang C.

Oncogene. 2015 Dec 10;34(50):6040-54. doi: 10.1038/onc.2015.52.

16.

A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.

Hiemer SE, Zhang L, Kartha VK, Packer TS, Almershed M, Noonan V, Kukuruzinska M, Bais MV, Monti S, Varelas X.

Mol Cancer Res. 2015 Jun;13(6):957-68. doi: 10.1158/1541-7786.MCR-14-0580.

17.

The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.

Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB; AOCS Study group., Bowtell DD, Harvey KF.

Oncogene. 2011 Jun 23;30(25):2810-22. doi: 10.1038/onc.2011.8.

PMID:
21317925
18.

Structural basis of YAP recognition by TEAD4 in the hippo pathway.

Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, Song H.

Genes Dev. 2010 Feb 1;24(3):290-300. doi: 10.1101/gad.1865310.

19.

Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.

Wang DY, Wu YN, Huang JQ, Wang W, Xu M, Jia JP, Han G, Mao BB, Bi WZ.

Chin J Cancer. 2016 May 20;35:47. doi: 10.1186/s40880-016-0109-z.

20.

Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer.

Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He J, Wang H, Xiao W, Li L, Chu Q, Pan Q, Yu Y, Sun F.

Hepatology. 2013 Sep;58(3):1011-20. doi: 10.1002/hep.26420.

PMID:
23532963

Supplemental Content

Support Center